Pharma & Bio
Technology
Choi Woo-sik, CEO of DEEPNOID Inc.: "Our Medical AI Foundation Model Has Surpassed Google's MedGemma"
“I was deeply impressed when I first encountered ‘ChatGPT’ in late 2022. Immediately afterward, we attempted a major pivot, shifting the company’s entire development strategy toward generative AI. ‘Me…
Technology
The Final Hurdle for Physical AI Is the Operating Room… Korean Medical Robots Drawing Global Attention
While robot errors on the factory floor result in defective products, errors in the operating room are a matter of life and death. This is why the operating room stands as the final gateway—the one wi…
Technology
Overcoming the Barriers of Visual Impairment... An Seong-wook, CEO of Renobit: The Story Behind His Mission to Hunt Down Cancer with Robotics and AI
"We are a company that uses robotics and artificial intelligence (AI) to address the reality where cancer goes undetected due to a shortage of personnel."
Ahn Seong-wook, CEO of RINORBIT. (Image co…
Technology
Hopes for Mifegyne Approval Boost Hyundai Pharm and Daehwa [K-Bio Pulse]
South Korea’s pharmaceutical and life sciences sectors saw broad declines on July 14.The pharmaceutical sector index fell 2.33% from the previous trading session. Of the 160 stocks in the sector, 41 r…
Lifestyle
“Will President Lee’s Remarks Lift the Ban on Mifegyn?”… Hyundai pharm Hits Daily Limit Up; DAE H WA PHARM CO., LTD., Which Holds a Stake, Also Surges [Bio Spotlight]
On the 14th, the domestic pharmaceutical and life sciences sectors showed a broad decline.The pharmaceutical sector index fell 2.33% from the previous trading day, with 41 of the 160 listed stocks ris…
Lifestyle
KOSDAQ Newcomer Remedy Jumps 67% During Trading Session; HLB INC. Hits Lower Circuit Breaker for Second Consecutive Day... LEMON COMPANY LIMITED Also Plummets [Bio Spotlight]
Remedy and HLB INC., both making their KOSDAQ debuts, saw mixed fortunes. Remedy surged nearly double its initial public offering (IPO) price during the trading session, fueling expectations of a “fir…
Lifestyle
Remedi Surges, HLB Hits Limit Down as FDA Setback Weighs[K-Bio Pulse]
The Korean biotech sector saw sharply diverging performances on July 13, with newly listed Remedi emerging as the day’s standout performer, while HLB extended its selloff following another setback fro…
Lifestyle
Jeon Tae-yeon, CEO of Alteogen: “Samsung Bioepis Patent Covers Process Technology, Not the Substance… No Impact on ALT-B4”
“Based on the patents currently disclosed, it is difficult to conclude that Samsung Bioepis has secured a new substance to replace ALT-B4. Therefore, I do not believe this will have a direct impact on…
Lifestyle
[Exclusive] Samsung Epics' SC Patent Lacks Inventive Step... Also Differs from 'Huons Co., Ltd. and Alteogen Inc.' Technologies
It has been confirmed that the patent technology related to a subcutaneous (SC) injection formulation filed by Samsung Bioepis was not recognized as novel or inventive during the publication stage of …
Lifestyle
"More Than 10 CDAs Expected to Be Signed"... BL Pharmtech Accelerates Follow-Up Deals After Bio USA
"Based on current developments, we expect more than 10 confidentiality agreements (CDAs) to be signed."These are the words of Jeong Gwang-ho, Chief Technology Officer (CTO) of BL Pharmtech.
Jeong G…